Michell Danielle L, Vickers Kasey C
Department of Medicine, Vanderbilt Univ. Medical Center, Nashville, TN, USA.
Department of Medicine, Vanderbilt Univ. Medical Center, Nashville, TN, USA.
Biochim Biophys Acta. 2016 Dec;1861(12 Pt B):2069-2074. doi: 10.1016/j.bbalip.2016.01.011. Epub 2016 Jan 26.
Lipoproteins, namely high-density lipoproteins (HDL), transport a wide-variety of cargo in addition to cholesterol and lipids. In 2011, HDL and low-density lipoproteins (LDL) were reported to transport microRNAs (miRNA). Since the original discovery, there has been great excitement for this topic and a handful of follow-up publications. Here, we review the current landscape of lipoprotein transport of miRNAs. HDL-miRNAs have been demonstrated to be altered in cardiovascular disease (CVD), including hypercholesterolemia and atherosclerosis. As such, HDL- and LDL-miRNAs may represent a novel class of disease biomarkers. Below, we review HDL-miR-92a and miR-486 levels in myocardial infarction and unstable angina, and HDL-miR-223 and miR-24 levels in coronary artery disease (CAD). Moreover, we address HDL's contribution to the total pool of extracellular miRNAs in plasma and differential distribution of miRNAs across HDL subspecies. Finally, we address current and future challenges for this new field and the barriers to such work. This article is part of a Special Issue entitled: MicroRNAs and lipid/energy metabolism and related diseases edited by Carlos Fernández-Hernando and Yajaira Suárez.
脂蛋白,即高密度脂蛋白(HDL),除了运输胆固醇和脂质外,还能运输多种物质。2011年,有报道称HDL和低密度脂蛋白(LDL)可运输微小RNA(miRNA)。自最初发现以来,这一话题引发了极大的关注,并出现了一些后续出版物。在此,我们综述了目前miRNA在脂蛋白运输方面的研究现状。HDL-miRNA已被证明在心血管疾病(CVD)中会发生改变,包括高胆固醇血症和动脉粥样硬化。因此,HDL-和LDL-miRNA可能代表了一类新型的疾病生物标志物。下文我们将综述心肌梗死和不稳定型心绞痛中HDL-miR-92a和miR-486的水平,以及冠状动脉疾病(CAD)中HDL-miR-223和miR-24的水平。此外,我们还将探讨HDL对血浆中细胞外miRNA总量的贡献以及miRNA在HDL亚类中的差异分布。最后,我们将阐述这一新领域当前和未来面临的挑战以及此类研究工作的障碍。本文是由卡洛斯·费尔南德斯-埃尔南多(Carlos Fernández-Hernando)和亚贾伊拉·苏亚雷斯(Yajaira Suárez)编辑的名为《微小RNA与脂质/能量代谢及相关疾病》特刊的一部分。